Bio-art and bio-design as economic activity

01Overview and value chain#

Markers EC: none — general EU art/design commerce | OECD: bio-materials, cross-cutting | Regulator: REACH (EU)

Bio-art and bio-design as economic activity covers gallery- and museum-commissioned design work built around living or biologically-derived materials — most visibly grown mycelium and other biofabricated materials shaped into art objects and design pieces — as economic activity distinct from the functional bio-material product companies (packaging, leather alternatives, construction materials) already covered elsewhere on this site. This is a genuinely thin commercial category: bio-art as gallery/exhibition economic activity is dominated by individual artists and grant- or academic-funded studios (university design labs, educational competitions) rather than a broad commercial vendor market with product pages. As of 2026 only one studio was confirmed with strong, on-topic, museum-exhibition-level evidence of ongoing commissioned bio-design work.

The key directions of bio-art and bio-design as economic activity are:

1. 3D-printed living-material design: using 3D printing techniques to shape living materials like mycelium into finished design or art objects, a genuine technical innovation distinct from conventional biofabrication molding.
2. Museum and gallery commissions: design work commissioned specifically for exhibition in museums and galleries, generating revenue through commission fees and exhibition licensing rather than product sales.
3. Materials-innovation design practice: a design practice organized around pioneering new biological material applications, positioning the studio’s work at the intersection of art, design, and materials science.
4. Grant/academic-funded bio-design: the broader field’s dominant funding model — university design labs and educational competitions (e.g. the Biodesign Challenge) rather than commercial commissions.

Sectoral value chain#

[Material innovation R&D] ──> [Design/artwork creation] ──> [Gallery/museum commission] ──> [Exhibition installation]
                                                                        │
                                                              (public/critical reception)
                                                                        │
                                                                        ▼
[Commission revenue/licensing] <─── [Exhibition run] <────────────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• 3D printing of living materials: printing techniques adapted to shape mycelium or other living biological substrates into precise design geometries.
• Biofabrication for design (not function): materials science applied to aesthetic and conceptual design objects rather than functional commercial products.
• Museum/gallery commissioning practice: the institutional and commercial mechanics of art/design commissioning, distinct from product manufacturing and sale.

02US#

No US studio with a dedicated, confirmed bio-art/bio-design commercial practice comparable to the EU anchor was found on a live screen. A “Biodesign Challenge studio” query surfaced only weak, single-mention evidence — the Biodesign Challenge itself is an academic/educational competition, not a commercial studio.

Academic/educational bio-design activity, no confirmed dedicated studio#

• Market context: the US has active academic bio-design programming (e.g. the Biodesign Challenge), but this article found no confirmed US commercial studio with museum/gallery-commission-level evidence comparable to the EU anchor.
• Reopen condition: if a US studio with confirmed commercial bio-art/bio-design commissions surfaces on a future screen, this section should be revised and the studio added to the table.

03CN#

No Chinese studio with a dedicated, confirmed bio-art/bio-design commercial practice was found on a live screen.

No confirmed dedicated studio#

• Market context: this article found no Chinese studio with confirmed, on-topic evidence of commissioned bio-art/bio-design work.
• Reopen condition: if a Chinese studio with confirmed bio-art/bio-design commissions surfaces on a future screen, this section should be revised and the studio added to the table.

04EU#

The EU has the one confirmed studio in this category.

3D-printed mycelium design, museum commissions#

• Studio Klarenbeek & Dros: a Dutch design studio confirmed via a dedicated Pinakothek der Moderne (Munich) museum exhibition, “Klarenbeek & Dros: Design of the Unusual,” described by the museum as the first designers worldwide to 3D-print mycelium, alongside additional coverage from Nieuwe Instituut and German architecture press of their bio-design work.

05Leading companies and research institutes#

06Tech stack and innovations#

The category’s core innovation is technical fabrication method applied to artistic and design ends rather than commercial product function.

1. 3D-printed mycelium fabrication:
   • Studio Klarenbeek & Dros pioneered 3D-printing mycelium, a living, thread-like fungal root structure, into precise design geometries — a genuine materials-science first credited to the studio by a major museum.
2. Museum-exhibition-scale commissioning:
   • The studio’s work being commissioned for a dedicated Pinakothek der Moderne exhibition reflects the commission-and-exhibition economic model that defines this category, distinct from product manufacturing.
3. Materials-innovation positioning:
   • The studio’s practice is explicitly framed around materials innovation rather than conventional design aesthetics, positioning its bio-design work at the intersection of art, design, and applied materials science.

07Value chains and production pipelines#

Industrial pipeline of a museum-commissioned bio-design work (general EU art/design commerce)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Material innovation R&D  │ ───> │ 2. Design/artwork creation │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Exhibition installation  │ <─── │ 3. Gallery/museum commission │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Exhibition run            │ ───> │ 6. Commission revenue/licensing │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Material innovation R&D

The studio develops a new technique for shaping a living or bio-derived material into a design object, such as the 3D-printing method for mycelium.

Stage 2: Design/artwork creation

The fabrication technique is applied to create a specific bio-design piece intended for exhibition.

Stage 3: Gallery/museum commission

A museum or gallery, such as the Pinakothek der Moderne, commissions the work for a dedicated exhibition.

Stage 4: Exhibition installation

The commissioned work is installed as part of the museum or gallery’s exhibition program.

Stage 5: Exhibition run

The exhibition runs for its scheduled duration, generating public visitor engagement and critical/press reception.

Stage 6: Commission revenue/licensing

The studio earns revenue through the commission fee and any related exhibition-licensing mechanisms, closing the economic cycle for the piece.